A groundbreaking new approach in cancer treatment has emerged, utilizing light to disable the mitochondria, the energy-producing organelles inside cancer cells. Researchers at Ohio State University have developed a targeted gene therapy using viral vectors, specifically engineered adeno-associated viruses (AAVs), that deliver genes designed to disrupt mitochondrial function directly to cancer cells. This therapy uses light to activate these genes, leading to the collapse of t

Hypophosphatasia (HPP), or "soft bone disease" is a rare genetic disorder that impacts bone and tooth development, leading to weak bones and other health complications. For years, enzyme replacement therapy has been the only effective treatment for HPP. This therapy involves injecting asfotase alfa, an enzyme that replaces the missing one in patients’ bodies. However, these injections must be given three to six times a week, which can be challenging for many patients. While t

Governor Kathy Hochul has announced New York Biogenesis Park, a $430 million cell and gene therapy hub set to transform the field on Long Island. Backed by a $150 million state investment, this 700,000-square-foot facility in Lake Success will focus on developing life-saving therapies, including treatments for cancer, genetic diseases, and chronic illnesses. The park will revolutionize medicine by repairing damaged DNA, modifying mutated genes, and engineering therapeutic cel

Heart disease is a leading cause of death worldwide, affecting millions at every stage of life, including infants born with congenital heart defects. These conditions often result in a weakened heart, leading to symptoms such as chest pain, breathlessness, and swelling. If untreated, they can be fatal. While surgeries can offer temporary relief, many patients eventually face heart failure. They may require a heart transplant—a challenging solution due to the scarcity of donor

Gene therapy is transforming the landscape of treatment options, and the recent FDA approval of BEQVEZ marks a significant milestone for individuals living with hemophilia B. This innovative one-time gene therapy replaces the need for regular infusions of clotting factor, offering new hope for patients suffering from this genetic disorder. Understanding Hemophilia B Hemophilia B is a genetic condition caused by mutations in the human factor IX gene, leading to a deficiency i

The FDA recently approved two groundbreaking CRISPR-based gene therapies for curing Sickle Cell Disease (SCD): Casgevy - developed by Vertex Pharmaceuticals and CRISPR Therapeutics Lyfgenia - developed by Bluebird Bio By targeting the BCL11A gene, these therapies successfully correct SCD mutations and increase fetal hemoglobin (HbF) levels in patients. This is exciting news for patients and families living with this painful disease, as it presents a potential cure rather than